Thromboembolic complications of sepsis: what is the incidence and pathophysiological mechanisms involved?
Holub
Michal
M
D054058:Acute Coronary Syndrome / Q000209:etiology; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000209:etiology* / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D054497:Phospholipases A2, Secretory / Q000037:antagonists & inhibitors; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012720:Severity of Illness Index; D020521:Stroke / Q000209:etiology; D013923:Thromboembolism / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D013997:Time Factors; D054556:Venous Thromboembolism / Q000209:etiology* / Q000503:physiopathology
D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D011486:Protein C; D011994:Recombinant Proteins; D054497:Phospholipases A2, Secretory; C421124:drotrecogin alfa activated